Are you or your child living with moderate to severe atopic dermatitis (eczema)?
A new clinical study is now enrolling adolescents and adults aged 12 and older who are starting or switching prescription treatment for atopic dermatitis.
What to Expect
Qualified participants will:
Receive study-related care from board-certified dermatologists
Be monitored closely throughout the study period
Have the opportunity to contribute to research that may improve treatment options for eczema in the future
Trial Requirements
- Are 12 years of age or older
- Have been diagnosed with moderate to severe atopic dermatitis
- Are willing to sign an informed consent form (or have it signed by a legal guardian if under 18
Additional criteria will apply, which the study team will review with you.
Urgently Recruiting
Trial Details
This study is evaluating nemolizumab (Nemluvio®), an investigational treatment that targets the causes of itch and inflammation beneath the skin. The goal is to learn more about how this treatment may help people living with chronic eczema.
All study-related care and medication are provided at no cost, and participants may receive compensation for time and travel.
